<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2024q2"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2024q2/ffd-2024q2.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <startDate>2024-10-04</startDate>
            <endDate>2024-10-04</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-04</startDate>
            <endDate>2024-10-04</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-116">S-8</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-117">S-8</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-118">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-119">0001444192</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-120">Acasti Pharma Inc.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-121">false</ffd:PrevslyPdFlg>
    <ffd:FormTp contextRef="rc" id="ixv-146">S-8</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-147">Acasti Pharma Inc.</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-148">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-149">Common Stock, par value $0.0001 per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="offrl_1" id="ixv-150">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_1"
      decimals="0"
      id="ixv-151"
      unitRef="Shares">1350000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-152"
      unitRef="USD">2.91</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-153"
      unitRef="USD">3928500.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-154"
      unitRef="pure">0.0001531</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-155"
      unitRef="USD">601.45</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="INF" id="ixv-156" unitRef="USD">3928500.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="INF" id="ixv-157" unitRef="USD">601.45</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="INF" id="ixv-158" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="INF" id="ixv-159" unitRef="USD">601.45</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-160">This Registration Statement registers 1,350,000 shares of common stock reserved for issuance under the Acasti Pharma Inc. 2024 Equity Incentive Pan (the "2024 Equity Incentive Plan"). Pursuant to Rule 416 of the Securities Act of 1933, as amended (the "Securities Act"), there are also registered hereunder such indeterminate number of additional shares as may become available for issuance pursuant to the 2024 Equity Incentive Plan as a result of the antidilution provisions contained therein, including stock splits and other similar transactions. The Proposed Maximum Offering Price Per Unit, the Maximum Aggregate Offering Price and the Amount of Registration Fee have been estimated solely for purposes of calculating the registration fee in accordance with paragraphs (c) and (h) of Rule 457 of the Securities Act based upon the average of the daily high and low prices of shares of the registrant's common stock on October 1, 2024, as reported on the Nasdaq Capital Market.</ffd:OfferingNote>
</xbrl>
